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I.

Background
The Orphan Drug Act (ODA) was enacted in 1983 in order to incentivize pharmaceutical

companies to engage in more research and development in order to create therapeutic molecules

to treat rare diseases. Under the Orphan Drug Act, the Food and Drug Administration (FDA)
defines the term "rare disease or condition" as any disease or condition that:

(A) affects less than 200,000 persons in the United States, or
(B) affects more than 200,000 in the United States and for which there is no
reasonable expectation that the cost of developing and making available in the
United States a drug for such disease or condition will be recovered from sales in
the United States of such d-g.'

If approved by the FDA

and developed into a treatment for one of these rare diseases, these

therapeutic or curative molecules are designated as "orphan drugs." Typically, a drug will
receive the designation of "an orphan drug" when the drug is "used to treat a disease whose
prevalence is so low that, in absence of incentives, commercializing the drug would unlikely
generate sufficient revenues to absorb the costs related to its development and marketing."2

In a report provided by IQVIA Institute for Human Data Science that was published in
October 2018, there are approximately 7,000 known rare diseases and/or conditions and only 500
orphan drug therapies that have been approved in the United States.3 These diseases affect
anywhere from 25 million to 30 million people in the United States, with more than half of that
number being children.a When compared with the total U.S. population, this equates to right

under 10% of Americans belonging to the rare disease community.s That means that almost 1 in

' 21 U.S. Code g 360bb(a)(2).
Andre' COt6, & Bernard Keating, I{hat is lVrong with Orphan Drug Policies?, l5 VALUE rN HEALTH, I l g5, I l g5

2

(Dec.20l2).
3

Orphan Drugs in the tlnited Stqtes: Growth Trends in Rare
Dere ScrpNcr, t, 2 (Oct. 2018).

Disease

Treatments,IevlA INSTrrurE
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a

Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments,supra note 3.
Rare Diseases: Facts and Statistics, GLosAL GENES; ALLTES rN RARE DTSEASE (last visited Jan. 3
https ://globalgenes. org/rare-di seases-facts-statistics/.
5

l, 2llg),

every 10 Americans are afflicted by one or more of these rare diseases.6 Despite this, the
currently available treatments are only available for 5oh of them.7 Rare diseases are often lifethreating or at the least life-limiting, and most can only be treated or managed, but remain

chronic conditions.8 Recently, however, there has been an increase in curative treatments which
provides hope for a better quality of life to those afflicted by these tragic rare diseases.e
Since its enactment

in 1983, the Orphan Drug Act today

has undergone several

amendments, and currently includes the following incentives:

(l)

seven years of market exclusivity for any unpatented drugs designated as
treatments for rare conditions; (2) tax credits for certain research and development
costs; (3) elimination or reduction of procedural fees; (4) fast-tracking of FDA
review and approval of applications pertaining to orphan drugs; and (5) f-ederal and
state grants for drug development (e.g., research grants from the National Institutes
of Health).ro
In theory, the Orphan Drug Act has the potential to save the lives of millions of suffering
people whose diseases were once completely overlooked by the pharmaceutical industry by

making treatment of rare diseases a lucrative opportunity. In application, however, the way the
law is written severely limits the accessibility of orphan drugs to those who need it. The primary
problem revolves around the monopoly market the Orphan Drug Act creates combined with the
high prices placed on such therapies. Through the Orphan Drug Act, drug manufacturers have
adopted a three-step strategy to profit off the vulnerabilities of desperate people affected by

tragic diseases. First, pharmaceutical companies apply for the orphan drug designation in order
to obtain the substantial economic benefits while they develop the drug, work on getting it

6

Rqre Diseases: Facts and Statistics, supra.
Orphan Drugs in the llnited States: Growth Trends in Rare Disease Treatments, supra note 3, at L
8
Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments, supra note 3, at 1.
e
Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments, supra note 3, at 1.
r0
Taeho Greg Rhee, Policymaking for Orphan Drugs and Its Challenges, l7 AvenrcAN MEDIcAL AssocrArroN
JouRNal oF ErHrcs 77 6, 77 6 (Aug. 201 5).
7

approved, execute marketing strategies, and subsequently sell the drug at preposterously high
prices due to the low target population.ll Second, once the FDA has approved the orphan
designated drug, pharmaceutical companies send representatives to doctors to convince them to
use

it in their practice and prescribe it to their patients.12 Third, they continue to profit by

obtaining new treatment indications to expand sales but keeping the initially astronomical
price.13

This paper will examine the history, development, enactment, applications, and criticisms
of the Orphan Drug Act. Lastly, this paper will provide an in-depth ethics analysis using Finnis'
theory of natural laws and natural rights to determine the morality of the act and how it can be

improved to better achieve its purpose.

II.

The Origin of "Orphan" Drugs: The Kefauver-Harris Amendments to the Food,
Drug, and Cosmetic Act
Although passed in 1983, the groundwork for the Orphan Drug Act began in the 1960s

when the primary issues that fueled the act became increasingly apparent. In 1962, when Senator
Estes Kefauver proposed a

bill that sought to amend the Food, Drug, and Cosmetic Act.la At the

core of his proposal was a desire to increase the government's control over the pharmaceutical

industry while also reducing the price of prescription drugs.l5 After significant revisions,
Congress passed the

bill in October of

1962, which indeed mitigated the serious issue of an

"increase price competition" among the pharmaceutical market.l6

rl COt6, supra note 2, at 1189.
'2 COtd, supra note 2, at 1189.
13
COtd, supra note 2, at 1189.
14
Koichi Mikami, Orphans in the Market: The History of the Orphan Drug Policy,0 Social History of Medicine
3 (Nov. 27,2017).
15
Koichi Mikami, supra note 14.
16
Koichi Mikami, supra note 14.
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However, some ofthe amendments demanded both a rigorous and costly approach to

clinical trials and authorized the FDA to be "the responsible govemment agency to oversee the
process of drug development

-

the 'gatekeeper' of the US pharmaceutical market."lT prior to

these amendments, properly labeled drugs that were for investigational use were permitted to be

freely distributed.l8 By stark contrast, the new amendments drastically changed this rute by
issuing many new regulations. For example, the amended Food, Drug, and Cosmetic Act
required drug sponsors to submit "investigational new drug" (lND) notices befbre starting any

clinical trials and would also be required to provide the FDA with lists ofall drugs already
undergoing clinical trials.le After the latter occurred, those same drug sponsors had the option

oi

either submitting an IND notice for each drug on the lists or just completely withdrawing the
drug and notifying the FDA ofthe reasons for doing so.20 This resulted in a quarter of the drugs
that were initially listed being withdrawn.2l With these new restrictions, the pharmaceutical

industry needed to refocus their research and development towards drugs that were worth the
extensive effort it would take to get them on the market and narrow the drugs they were already

working on for efficiency and productivity.
In June of 1963, the Commission on Drug and Safety22 held a conference addressing the
issues and concems raised after the passage of the bill.23 Beyond the concems of the now

frustrated biological and chemical manufacturers, there was also the issue of a clear preference

for commercially valuable drugs that was severely agitated by the 1962 amendments.
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Mikami,

supra note 14, at 16.
supra note 14, at 4.
supra note 14, at 4.
supra note 14. at 4.
supra note 14, at 4.
22
The commission was described as "a body ofexperts drawn from industry and academia on pharmaceuticals, set
u-p in 1962 by the Pharmaceutical Manufactuers Association (pMA)." Koichi Mikami, supra note 14,
at 4.
':3 Koichi Mikami, supra note 14, at 4.
18

During the conference, a representative of the American Society for Clinical
Investigation, Grant E. Liddle, surmised that "in most cases, the decision to withdraw was due to

their 'low commercial priority."'24 In this same conference, the chairman of the Committee on
Drug Dosage, Harry C. Shirkey, used the word "orphan" in relation to these low commercial

priority drugs, which was the first time on record that the term was used.2s Shirkey used the
phrase "pharmaceutical orphans" to describe and express a deep concern for increasing numbers

of drugs approved for adults, but not for children and infants, which ultimately left children with
fewer therapeutic options.26 In an editorial comment written by Shirkey five years later, he
deduced like Liddle that these again was solely due to the small sales potential

of

"pharmaceutical orphans," especially when compared to the general cost of obtaining FDA
approval and the additional cost of receiving FDA approval for pediatric use of the drug.27 Later,
the idea of "orphans" was again articulated by George P. Provost2s in order to describe
substances that were still kept in hospital pharmacies from before 1962, but that was not

approved for clinical use under the new regulations."2e Provost also suggested that the reasons
producers stopped seeking approval of such "orphan drugs" was due to insufficient

profitability3o:
Shirkey and Provost both observed that in the past pharmaceutical companies had
supplied some drugs at a financial loss as a service to the public-so-called "public
service drugs" or "service drugs". Assuming that it was the increased cost of
obtaining marketing approval that jeopardized this practice, they argued that
doctors and pharmacists should do more to help companies secure approval by
collecting relevant information about unprofitable drugs. I I

24

Koichi
Koichi
26
Koichi
27
Koichi
25

28
2e

Mikami, supra note 14, at 4.
I{ikami, supra note 14, at 4.
Mikami, supra note 14, at 4.
Mikami, supra note 14, at 4.

Provost was an editor of the American Journal of Hospital Pharmacy. Koichi Mikami, supra note 14, at 4.

Koichi Mikami, supra note 14, at 4.
30
Koichi Mikami, supra note 14, at 4.
3t Koichi
Mikami, supra note 14, at 4.

While the concept of "orphan drugs" was often expressed in the 1960s, it was still not heavily
debated at that time. Instead, the debates focused on other amendments to the Food, Drug, and

Cosmetic Act. For example, during the 1970s, more emphasis was placed on concems expressed
by the pharmaceutical industry: that the new regulations caused "drug lag," which focused
around how much longer it was taking for effective drugs to reach the market.32

However, that almost changed in 1975 when the FDA finally began to recognize drugs of

limited commercial value. Specifically, the associate director for new drug evaluation at the FDA
Bureau of Drugs, Marion J. Finkel, gathered a committee that "contemplated possible incentives

to encourage pharmaceutical companies to produce such drugs, but concluded that the reasons
they were neglected were too diverse to permit meaningful recommendations."33 Thus, no action
was taken despite the knowledge and recognition that something could be done.

III.

The Passage of The Orphan Drug Act: Senator Kennedy's Efforts to Encourage
the Research and Development of Orphan Drugs

In 1977, the members of Congress were repeatedly and increasingly notified of
pharmaceutical companies' neglect to develop drugs that only treated a small percent of the

population due to their limited commercial value.3a For instance, the Congressional Commission
for the Control of Huntington's Disease and Its Consequences3s elaborately discussed their
concerns about this same rising trend: pharmaceutical companies were not interested in

developing therapeutic and curative drugs for diseases that only affected a relatively small

32

Koichi Mikami, supra note 14, at 5.
Koichi Mikami, supra note 14, at 5.
34
Koichi Mikami, supra note 14, at i .
33

35

The Congressional Commission for the Control of Huntington's Disease and lts Consequences was created by the
Public Health Service Act of 1975 and chaired by Marjorie Guthrie. Marjorie Guthrie was a founder and the
president of the Committee to Combat Huntington's Disease, a patient suppolt group. Koichi Mikami, supra note 14,

at7.

amount of the U.S. population.36 After reporting their agitations to Congress, Senator Edward M.
Kennedy promoted and included the research and development of what was then called "drugs

limited commercial value" in his proposal to create

a

National Center for Clinical Pharmacology

in his Drug Regulation Reform bill.37 Consequently, the FDA began to study the orphan drug
problem in 1978 by convening an Interagency Task Force3s in which they focused more on a
solution to the problem instead of wasting time establishing definitive facts and figures.3e
The Interagency Task Force briefly acknowledged the practices of pharmaceutical
manufacturers before 1962 in which they would supply service drugs even at the loss of profits
and used this trend as evidence of the industry's capacity to synthesize such drugs as well as

their willingness to.40 Yet, that trend was now almost extinct, with the only logical factor to the
shift being the increased cost of obtaining FDA approval.al Thus, in order to remedy the
industry's deterrence to manufacture service drugs, the report recommended a financial support
program to aid in clinical trials until the drug gained market approval.a2 The task force also
suggested that

"[a] new FDA advisory board should also be set up 'to encourage voluntary

industry action as a matter of public interest and ... accord appropriate recognition to firms
which participate on the basis of humanitarian concem."'43 These ideas are reflective of the
current incentives in the Orphan Drug Act and thus laid the groundwork for it.
Subsequently, the FDA's adopted a new approach aimed to offset both the cost

of

obtaining market approval and encourage pharmaceutical companies to voluntarily commit to

36
37

Koichi Mikami, supra note 14, at 7 .
Koichi Mikami, supra note 14, at7.

38

The Interagency Task Force was chaired by the same aforementioned Marion J. Finkel. Koichi Mikami, supra
note 14, at7.

3e
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Mikami,
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Mikami,
Mikami,
Mikami,

supra note 14, at 7 .
supra note 14, at 8.
supra note 14, at g.
supra note 14, at 8.
supra note 14, at g.
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of

producing more service drugs by providing financial and organizational support, just as the Task
Force proposed.a4 However, despite the FDA's findings and recognition regarding the obvious
orphan drug issue, Kennedy's Drug Regulation Reform bill still failed in both 1978 and 1979.45
Nevertheless, this was not the death of the reformation efforts. In fact, the matter continued to
stay before Congress due to the increased amount of interventions from patients and practitioners
alike.a6

Finally, the attempted development of a treatment for myoclonus by researcher Melvin Van
Woert was the final push the legislators needed to set the passage of the act in motion.aT
Myoclonus is the sudden and involuntary jerking of groups of muscles, which can indicate
serious underlying disorders, such as brain tumors, kidney failure, chemical or drug poisoning,
head or spinal cord injury, or stroke.48 More often, myoclonus is caused by a wide array

of

neurological disorders: multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's, and
Creutzfeldt-Jakob disease.ae Thus, there was a severe need in the market to take Van Woert's
research and develop it to be commercially manufactured and distributed. When Van Woert
approached several organizations for help, the FDA, U.S. National Institutes of Health (NIH),
and the PMA, they all turned him away and were unable to offer any solutions.so This instigated

myoclonus patient Sharon Dobkin, to contact a local representative, Elizabeth Holtzman,

convincing Holtzman that immediate legislative change was of the utmost importance.5l Though
this seems like a small anecdote in the large history of the Orphan Drug Act, it was Holtzman's

44

Koichi
Koichi
46
Koichi
47
Koichi
4s

Mikami,
Mikami,
Mikami,
Mikami,

supra note 14, at 8.
supra note 14, at 8.
supra note 14, at 8.
supra note 14, at 8.

a8

Myoclonus Fact Sheet, Ne.rloNel INSTITUTE oF NEURoLoGICAL DISoRDERS AND StRore, (last visited Jan.
2019), https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myoclonus-Fact-Sheet.
ae
Myoclonus Fact Sheet, supra note 48.
so
Koichi Mikami, supra note 14, at8.
sl Koichi Mikami, supra note 14, at 8.
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bill, supported by Representative Waxman, that laid the foundation for the actual language and
enactment of the Orphan Drug Act itself.

IV.

The Orphan Drug Act is Born
It was in early 1980 when Elizabeth Holtzman introduced her bill that was based on

recommendations from The Interagency Task Force.52 The bill itselfoutlined measures in order

to "assist the development of drugs for diseases and conditions oflow incidence" by providing
both administrative and economic assistance to pharmaceutical companies so that they could
research and develop drugs like the one Van Woert sought to commercialize.s3 The

bill was

supported and pushed forward by Representative Waxman, who was well-known lbr his activism

of health care reform.sa Waxman had recently been appointed the chair oithe House
Subcommittee on Health and the Environment and, and after leaming of Holtzman's bill.
arranged for it to be presented to the committee in June

ol

1980.i5 Ultimately. the Holtzman

bill

failed when presented to the House of Representatives, but that did not stop Waxman nor should
the rejection of the bill be considered a failure.

s6

The Holtzman Bill and waxman's persistent

advocacy raised significant awareness for the dire need of a legislative effort to address the issue

52

Koichi Mikami, supra note 14, at 8.
Koichi Mikami, supra note I4, at 8.
54
Koichi Mikami, supra note 14, at8-9.
55
Koichi Mikami, supra note 14, at 9.
56
Koichi Mikami, supra note 14, at 9 ("The Los Angeles Times published a small article about it. This caught the
eye of Maurice Klugman, who was then suffering fiom a rare form of cancer, and he and his brother, actor Jack
Klugman, produced an episode in the television drama series Quincy MD. based on the story ofthe family that had
asked Waxman for help. The episode was effective in increasing the visibility ofpatients and families and building
public support for legislatiye effort to address the problem of drugs of limited commercial value, and is remembered
5r

by many as lhe moment when 'the ball began to roll'.").
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surrounding drugs of limited commercial value. Only three years later, Waxman took the matter

into his own hands and submitted the bill that became the Orphan Drug Act of 1983.s7
The stark difference between the bill Waxman proposed and Holtzman's proposal was
the way

it framed the issue of the orphan drugs, which is likely why the House was moved

enough to finally resolve the orphan drug issue. Holtzman merely pushed for the

FDA's support

by trying to provide funding to drugs that both already existed and showed evidence ofsafety
and effectiveness.58 Holtzman's

bill embodied the view of Dobkin, the myoclonic patient, who

argued in front ofCongress about her personal experiences with the treatment an orphan drug
can provide: "the worst thing that can happen to a person is to hold a treatment in his hand, see

the miracles

it can bring, and then have it pulled away."se This issue is clearly an important one,

but the solution Holtzman and Dobkin proposed was too narrow and very limited, which is likely
the reason

it failed when presented to the House of Representatives. Without

a doubt,

Holtzman's bill would help many lives, but what about the lives ofthose who never even had the
blessing of holding that miracle in their hand, to begin with? By ignoring those people, Holtzman

failed to provide a solution that would extend to all members of the rare disease community,
leaving numerous people afflicted with diseases that had no treatment options with absolutely no
hope of a better future.

When the Waxman bill was presented in front of Congress, Waxman invited the Vice
President of the Tourette Syndrome Association, Abby S. Meyers, to speak Congress about her

personal experience with rare diseases and conditions.60 Meyers brought to light a new view

of

the orphan drug issue, one that encompassed those who hadn't even had that treatment, that

5?

Koichi
Koichi
5e
Koichi
60
Koichi
58

Mikami,
Mikami,
Mikami,
Mikami,

supra note 14, at 9.
supra note 14, at 9.
supra note 14, at9. (quoting House committee, Drug Regularion Reform, g6th Congress.3l.)
supra note 14, at 9.
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miracle, in their hands.6r In a powerful testimony she gave, Meyers stated exactly how the bill,

if

enacted, would provide that same help, and more importantly, hope:

Millions of Americans who suffer from rare diseases live without hope. We believe
that there are not enough dollars among patients who suffer liom sickle cell anemia,
Cooley's anemia, Huntington's disease, cystic fibrosis, Wilson's disease, Tay Sachs
disease, dystonia, and many, many more, to make the manulacture

ofa therapeutic

drug profitable.62

Meyers spoke to give a voice to those who were suffering everywhere, and it directly
impacted the scope ofthe orphan drug problem. The goal was no longerjust to streamline the
development and production ofpresent treatments tbr rare conditions, but instead to also
promote the development of completely new drugs for those inflicted by rare diseases as well.

Without the problem and solution being widened by people like Waxman and Meyers. the
Orphan Drug'Act would have never developed into the influential act it has become toda1,,

providing treatments and cures for those suffering from rare conditions on a global scale.

While Meyers and Waxman were on the lront lines of this legislative battle, those
inflicted with the disease were still very much involved in the process. In fact, they serued as a
major inspiration to Meyers speech in from of Congress, as Meyers spent time with a plethora of

inflicted patients to gather their thoughts on this major flaw in the pharmaceutical injury. It was
these patients that really gave the issue a first-person viewpoint to help expand and yet articulate

the issue: "these patients indicated that the scope ofthe orphan drug problem needed to be
expanded, to include notjust the problem olsecuring access to existing but unapproved drugs, to

the larger question ofhow to promote the development ofnew drugs for rare conditions."63

6t

Koichi Mikami, supra note 14, at 9- 10.
Koichi Mikami, supra note 14, at 9-10.
6r Koichi Mikami. supra note 14, at 10.
62

1rt

This "future-oriented" view of the orphan drug problem was at the center of Waxman's
proposal during the second hearing of Holtzman's bill, but when he brought his own bill

forward, he executed his sympathies and goals by including provisions that would streamline the
creation of orphan drugs and incentivize pharmaceutical companies to pursue the development

of

these drugs. For instance, he posited that a single, but well-controlled clinical trial when

combined with post-marketing surveillance should be enough for FDA approval.6a As for
incentives, he propositioned that pharmaceutical companies should receive tax credits
proportionate to clinical testing costs of orphan drugs and that these companies should be granted

exclusive seven-year marketing rights for the drug. Lastly, Waxman framed the entire orphan
drug issue as a case of market failure.65 In doing so, several organizations opposed to the bill
conceded, which gave Waxman the support of both consumers and potential orphan drug
suppliers.66 Once this support was secured, the

bill

passed

with ease, as the House of

Representative approved Waxman's bill with only minor amendments.6T In January of 1983,

everlthing became official when U.S. President Ronald Reagan signed the Orphan Drug Act into
law.68

V.

The Beneficial Impact of the Enactment of Orphan Drug Act
Without question, the Orphan drug act has achieved its primary purpose to a certain

degree, giving hope to many people afflicted with rare diseases and has certainly increased the

pharmaceutical industry's interest in developing new therapies. Before the enactment of the

64
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supra note 14, at 10.
supra note 14, at I l.
supra note 14, at 13.
supra note 14, at't3.
supra note 14, at 13.
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Orphan Drug Act, only l0 drugs were available to treat rare diseases.6e By contrast, between
January 1983 and May 2010, 353 orphan drugs were approved in the United States by the
FDA.70 Since then, a report titled Orphan Drugs in the []nited States released in October 2018
stated that currently there are over 500 orphan drugs on the market.Tl Proponents of the act

severely stress this, among other things, when evaluating the true benefits and influences ofthe
Orphan Drug Act. Essentially, they argue that the policies enacted by the Orphan Drug Act have
had enormous contributions, focusing especially on "the extension

ofan improvement in quality

of life, the acquisition of new knowledge about other types of illnesses. the considerable boon to
the industry, especially in biotechnology, and the accelerated processing of drug approval
applications."T2

Unfortunately, these numbers are misleading for several reasons. First, the drugs lall into
a

narrow range a few therapeutic families. leaving many rare diseases still untreated.T3 Second,

the few therapeutic families these orphan drugs are limited to are "those that olfer a significant

tumover."74 For example, studies have shown that "orphan drugs used to treat rare cancer are the
most profitable."7s Third, while hundreds ofnew molecules are available, they are not accessible

to patients due to unnecessarily high prices.76 These three points are at the center ofthe debates
and agitations

VI.

6e
70

ofthe Orphan Drug Act, which will be analyzed lurther in the next section.

Criticisms of the Orphan Drug Act

Taeho Greg RIee, supra note 10.
Cotd, supra note 2, at I 186.

11

Orphan Drugs in the Llnited States: Crowth Trends in Rqre Disease Tredtments, supra note 3.
Cotd, supra note 2, at I I 86.
7r
C6td, supra note 2, at I 186.
74
Cotd, supra note 2, at I I 86.
75
Taeho Greg Rhee, supra note lO, at'777; see Cdte, supra note 2, at I 186.
76
Cotd, supra note 2, at I186.
72
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a.

A Large Number qf Orphon Drugs are Primarily Limited to a Narnn'Group

of

Therapeutic Families
On its face, the large number oforphan drugs that have been approved gives the

impression that the act has allowed for new molecules to treat a wide variety ofillnesses.

However, only "five therapeutic classes account for

will

be discussed in descending order.77 Out

7

5'Yo

of the market for orphan drugs," which

ofthe 353 orphan drugs that were FDA approved by

2010, 95 were directed at the oncology class. This was followed by 54 orphan drugs solely fbr
metabolic disorders,4l for hematology,

4l lor infectious diseases,

diseases. The remaining 92 were distributed among

and 30 lor neurological

1l other therapeutic

classes: "psychiatric,

musculoskeletal, gastrointestinal, dermatologic, respiratory, ophthalmologic, hepatic/biliary,

immunology, cardiovascular, [ ] genitourinary disorders, and . . . treatment of
intoxications/envenomations."T8 Even as recent as 2015, data has shown that cancer drugs were

still the predominant therapeutic class targeted bv orphan drugs, making up 95 out olthe 400
plus orphan drugs at that time.Te

b.

Pharmaceutical Companies are " only in it .for the Money"

Many have theorized that distribution phenomenon illustrated above is evidence that
pharmaceutical companies are using the Orphan Drug Act to merely tum a profit.8o As evidence

of this theory, many authors, analysts, and scientists alike brought attention to numerous orphan
drugs on the market that "had a financial retum that significantly outmatched the investments

77

Cotd, supra note 2, at I 186.
COtd, supra note 2, at I 186.
7e
Taeho Greg Rhee, supra note 10, at77'7.
80
Cote, supra note 2, at I 186.
18
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involved."8l In two separate publications, written by Seachrist82 and Casali83, the same argument
is advanced: that this profitability connected to orphan drugs in the oncology realm, at least in
part, can be explained by the frequent off-label use ofthese drugs.8a Going further, in another
report by Thorton litled Opportunities in Orphqn
Returns

Drugs

Strategies

for Dewloping Maximum

jlom Niche Indicators, Thorton contended that "manufacturers

have an incentive to

abandon the traditional business model based on the mass sale of drugs intended for general care

treatment and to tum to targeted drugs with high commercial potential."85
These theories and observations are backed by frightening numbers from compilations

that analyzed the whole population of orphan drugs and the insurmountable retum of investment
they provided for their manufacturers. In 2008, 43 trademarked treatments for rare diseases
generated a total ofone

billion annual sales globally.86 Another 33 trademarked drugs with

orphan designations achieved annual sales that ranged from $100 million to

$ 199

million:

Of these, 19 were approved for orphan applications, 7 had global annual sales of
$100 million to $199 million, t had global annual sales of $200 million to $299
million, 5 had global annual sales of $300 million to $399 million, 3 had global
annual sales of $400 million to $499 million, 5 had global annual sales of $500
million to 599 million, and 3 had global annual sales of $600 miltion to $999
million in 2008.87
In conclusion, pharmaceutical companies are arguably are abusing the incentives contained in
the Orphan Drug Act in pursuit of highty lucrative opportunities.
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COtd, supra note 2, at I 185.
Seachrist L., Se, ators seek reform ofOrphan

Drug Act,85

JoURNAL oF NATIoNAL CANCER INSTITTITE 1984

(Dec. 15, 1993).
83

Casali, The off-label use o/ drugs in oncologt: a position paper by the European Society

l8

ANNALS oF ONCoLocy 1923 (Dec. 18, 2007).
84
Cdtd, supra note 2, at t 86.
85
Cotd, supra note 2, at 186.
86
Cdtd, supra note 2, at 186.
87
Cote, supra note 2, at r86.

Iu

for Medical Oncolog,,,

c.

Availability does not Equol Accessibility

-

The Unexplainably High Prices

of

Orphan Drugs
The pharmaceutical industry has contributed few treatment options for many therapeutic
classes that present low commercial value, leaving many people suffering

lrom rare diseases

with little to no hope to manage the symptoms of their respective conditions. Despite this, an
argument can still be made to the positive, that although the intentions of pharmaceutical
companies are fueled by money, at least people in the lucrative therapeutic classes are able to

receive treatment. As the saying goes, "something is better than nothing.'' The availability

of

orphan drugs in the targeted therapeutic classes, in theory, should benefit the members ofthose
classes, providing hope

for

a better

quality ollife. However, availability does not equal

accessibility. This leads to the third major criticism of the Orphan Drug Act: such patients can't
afford the orphan designated medications due to outrageously high prices.88
For instance, one Orphan drug, Cerezyme, was developed to treat Gaucher disease, which
affects about 2,000 patients in the United States.8e Yet, Cerezyme "costs as much as $400,000
every year for an adult patient."eo Another example is Fabraxyme,el a therapeutic molecule
developed to treat Fabry Disease, a lysosomal storage disorder that impairs cells' ability to
function.e2 Fabraxyme costs each patient approximately $300,000 annually.q3 The annual
revenue for other drugs has only gone up in recent years. The most expensive example to date is

88
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a drug marketed as Soliris,ea treatment

for diseases like "paroxysmal noctumal hemoglobinuria

(PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive generalized myasthenia gravis (gMG)."ei Soliris costs more than $500,000
dollars per patient annually.e6 Analysts predict in 2018 the cost of Soliris will be supplanted by
either a "spinal muscular atrophy drug Spinraza, which costs $750,000 or BioMarin's Brineura

for Batten disease, with an annual cost of $702,000."e7
Examples like this are not uncommon. Andr6 C6t6 asse(s that "[t]he prices charged fbr
these new orphan drugs frequently exceed the usual pharmacoeconomic scales and the thresholds

ofsocial acceptability."e8 This major consequence olthe Orphan Drug Act's incentives comes
down to lack ofpatient bargaining power and greedy pharmaceutical companies. Drug
manufacturers are "free to set their own introductory prices."ee This practice often leads
companies to choose a price that

will maximize its profits,

and as of now, this is completely

within their legal rights.r00 Additionally, payers' are precluded lrom any involvement in
negotiating the prices due to a common practice called "disease sub-setting," "salami-slicing." or
"disease stratification."r0r This practice occurs when a company "split[s] up a disease into
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several sub-diseases that qualiry as rare diseases."l02 Lastly, insurance companies often deny

reimbursements for these drugs due to concems from all payer organizations. This leads patients
to tragic disappointments, as their only option after being denied reimbursements is to either pay
up or say goodbye to the hope ofachieving a better quality ollif-e.

VII.

The Orphan Drug Act, while Pure in Purpose, is Flawed

These practices described above are the result, whether direct or indirect.

ofthe

incentives built into the act in order to promote the development ofdrugs therapies to treat or
cure rare diseases, which raises the question. are the incentives really doing enough? In an

altemative view, some researchers even suggest that the issue instead is the nature ofthe
pharmaceutical industry itself, posing the question of whether, even ifgiven better incentives to
focus on the neglected rare diseases, the pharmaceutical industry would continue to pursue only

commercially lucrative areas.r0l Taeho Greg Rhee suggests that if the accessibility oforphan
drugs is to be improved, relevant policies in the Orphan Drug Act should be reformed to promote
faimess and equity.l04 According to C6t6:

In the medical setting, faimess is defined with respect to the aim of providing
citizens with equal access to health resources, which matches their actual health.
Faimess requires a positive action by the state [or govemment] when the market
does not provide a good match between investments and health [care] needs.
Finally, faimess requires that the baniers to access should be morally justifiable."ros
Thus, ideas of faimess, equity, and equality are what inspires critics who advocate for
amendments to the Orphan Drug Act. The Orphan Drug Act itself was created to assist a

population ofpeople in dire need of medical treatment, and yet, the data presented clearly shows
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that it has not fully achieved that purpose. There is still a large population ofpeople facing
detrimental diseases whose needs for help are still being ignored. Can this be considered
faimess? In other words, are the results of the Orphan Drug Act, as C6t6 puts it, "morally

justifiable?" The following section will analyze such by exptoring the ethical nature ofboth the
Orphan Drug Act and its effects in the medical community.

VIII.

Introduction to Finnis'Ethical Theory

In Natural Law & Natural Rights.l06 Finnis delves into a modem theory ofthe purpose

of

law and life, reminiscent of the much older works of Aquinas and Aristotle. The idea olnatural
justice, according to Aristotle, is a rule ofequity that corrects the deficiencies olthe law through
reason and its universality.l0T This is what makes Finnis'modem notions ofgoods and justice so

valuable, as through the philosophies behind natural law and natural justice can we come to a
superior analysis of the law that transcends conventional ideas ol legal justice.

108

Atthe hearlof

Finnis' theory are three fundamental concepts that will be used to come to a better ethical
understanding ofthe Orphan Drug Act:

(l)

the seven basic goods, (2) the nine principles

of

practical reason, and (3) the three elements ofjustice. It will be proven through these three
concepts, that at its heart, the Orphan Drug Act serves a moral purpose to correct a harmful

inequity in the medical community. However, its application has caused a large and non-

justifiable disparity among different subsets ofpeople. Thus. amendments are required in order
to realign the effects ofthe Orphan Drug Act with itsjust intentions.

John Fimis, Nalural Law & Natural Righrs I (2d ed.20l l).
Michael Ambrosio, Natural Law as a Wisdom Tradition, in Proceedings ofthe Center for Catholic Studies:
Knowledge and Wisdom 31, 3l (Seton HaU Univ.) (1998).
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IX.

Seven Goods

Finnis asserts seven fundamental, equally important, and self-evident goods necessary for
humans to have a valuable and

fulfilling existence: life, knowledge, play,

aesthetic experience,

sociability (friendship), practical reasonableness, and "religion."l0e For the purposes of this
analysis, the Orphan Drug Act will bejudged using four out of the seven basic goods, as these

four are most applicable to the law and its implications: life, knowledge, sociability, and
practical reasonableness.

a. Lfe
Generally, the value of life is driven by the innate need in humans for self'-preservation,

but it's meaning is expanded on further by Finnis.r

I0

In natural law. life signifies much more,

dignifying every aspect of life such as vitality. health. freedom fiom pain. and the transmission
of life through procreation.lll These necessities drive humans into

a

community govemed by

laws because they lead to the "recognition, pursuit, and realization ofthis basic human purpose

(or intemally related group of purposes)."r12
When considering the concept

ollife

and its role in the Orphan Drug Act, the connection

is clear, as the primary purpose of the Orphan Drug Act is to value life, specifically, to value the

lives ofthose previously disregarded by the pharmaceutical industry. As albrementioned.
pharmaceutical companies invest and develop commercially valuable treatments, and have for

quite some time. Up until the orphan Drug Act, only common diseases that were lucrative, such
as diabetes, heart disease, and common cancers, were the focus

of pharmaceutical research labs

and manufacturers so that such companies could tum a profit. However today, this practice stays
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the same as pharmaceutical companies use their resources towards lucrative opportunities when
they could easily put those resources to providing therapeutic and curative treatments to diseases
that might not be as profitable. This devalues the life ofanyone suffering from a rare disease. In
fact, this practice completely defiles the value of life as defined by Finnis. Such practices strip

vitality, health, and freedom from pain lrom the members of the rare disease community,

a

natural right all people are entitled to. notjust the people who can help the makers of medicine
make money.

Aside from the effects of the Orphan Drug Act, the law itself, in some populations, has
helped preserve life. The Orphan Drug Act put a value on an ignored population by incentivizing
otherwise greedy pharmaceutical companies into researching and developing a treatment for
these people. By Finnis' standard, this boosts the argument that the act

itselfis in line with the

ethics set forth by Finnis' understanding ofnatural law. While there are flaws in its application,
e.g., the many nonlucrative diseases that have minimal to no treatment options whatsoever, this
can be overcome through reconsideration and amendment. Thus, standing alone, the act is in line

with granting the natural right of life to all people, no matter the disease, but through the
furtherance ofknowledge olthe issue (and in some way sociability), the act's effects could also
achieve this purpose. This will be discussed and expanded upon in the subsequent sections

b.

Knowledge and Sociability

When it comes to the values of knowledge and sociability, they are deeply intertwined in

all aspects ofthe Orphan Drug Act. Finnis explains that knowledge is rooted in curiosity and is,
in its simplest terms, "getting to the truth olthe matter.''rrr As

a practical matter, knowledge is a

good that one should pursue in life, white ignorance should be avoided.rra Going further. Finnis

rrr Finnis, supra
note l06, at 61.
ra
Finnis, supra note l06, at 63.
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defines sociability as a spectrum that ranges from the value ofpeace and harmony among people,
through the forms of human community, and to the creation of true friendship.ll5 In regards to
the Orphan Drug Act, knowledge and sociability ignited its birth, ignorance allowed its effects,
and knowledge and sociability can change

it

so that

it is restored to ajust law,in all

aspects.

As a general maner. legislalive a\ areness lknowledge)ofan issue is the key to enacting
a

law. Although, when the Orphan Drug Act was enacted, both knowledge and sociability were

equally important in its passing, as one flourished the other and vice versa. As discussed in the
more historical section of this paper, it was the gathering of a community ofpeople suffering

from debilitating diseases that caught the attention ofinfluential legislators. It was the friendship
between those legislators and the afflicted that brought personal testimony to the floor

ofthe

house of representatives in order to humanize the issue. Hearing data objectively when compared

with seeing someone suffering right in front ofyou is moving, memorable, and the push needed
to bring significant attention to the orphan drug problem. Thus, while knowledge certainly
played an important role in the Orphan Drug Act's enactment, it was sociability that facilitated a
better understanding ofthe issue, increasing that key legislative awareness.
Conversely, the FDA's current ignorance is unjustifiable. The law was meant to provide
hope for all, and yet, all of the statistics and examples provided throughout this paper are
evidence that the law is being abused and segregating classes ofpeople. It is known that
therapeutic areas that are not commercially valuable are being ignored. As a result, those with
rare diseases are being put into two categories:

(l)

individuals sufl'ering from a rare disease

whose treatments, ifdeveloped. would be highly lucrative. and (2) individuals sutfering l'rom a
rare disease whose treatments project little to no commercial value. One should not be judged on

rr5

Finnis, supra note 106, at 88.

l)

whether their condition can be capitalized on nor should one be discriminated against for that

very sarne reason. This data has been around for centuries, and yet there has been no legislative
change. This leads to only one conclusion, that the value ofknowledge is being blatantly ignored

by the FDA and legislators alike. Under Finnis' standards, this is unacceptable because
ignorance is to be avoided, and ignorance is the inhibitor of truly fixing the unjust effects of the
Orphan Drug Act.

Using Finnis' concepts ofknowledge and sociability, this injustice can be remedied to
align with the natural law of the world and the natural rights all humans deserve. Parallel to the
action ignited in the past, there are two solutions using these basic goods:

(l)

the community

of

those afflicted with rare diseases could come together to inspire legislative change like they did

when the act was first invented, or (2) the FDA will respond to the outcry ofthese patients and
the criticisms ofscientists, authors, and reports displaying the disparity by changing a flawed

law Sociability will

increase knowledge, and with enough social pressure, the FDA can no

longer contend that it is justifiably ignorant.

c.

Practical Reasonableness

Practical reasonableness is the source ofchoosing one's actions and lifestyles by using
one's orm intelligence to make effective determinations and choices.r

16

In addition to shaping

one's character, practical reasonableness is a good that is applied a measuring system involving
the assessment ofbalancing freedom to choose with reasonableness in one's actions.llT Thus
practical reasonableness is a complex concept "involving freedom and reason, integrity and

authenticity."r

r8

Practical reasonableness, though seemingty a good that aflects only the

r16
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individual using it, can be applied more broadly to make ethical determinations about more than
one's actions. As stated before. it is a measuring system. so the algorithm ofpractical
reasonableness can be used in all ethical conclusions, including the law. The following section

will

assess the Orphan

Drug Act using practical reasonableness in order to provide an extensive

moral analysis ofthe law and its effects.

X.

Nine Principles of Practical Reasonableness
As stated above, practical reasonableness is the mechanism in which one can make

correct judgments about what isjust.rre This mechanism uses nine principtes, all of which are

"interrelated and capable ofbeing regarded as aspects one ofanother."l20 The product of the nine
principles ofpractical reasonableness is the morality ofthe matter beingjudged.12l Therefore, at
the conclusion of this section, the justness olthe Orphan Drug Act and its effects will be
revealed.

a.

First Principle

The first principle ofpractical reasonableness is refened to by both Finnis and Rawls as

"a rational plan of life."l22 This involves having a harmonious set ofpurposes, implicitly or

explicitly, which ultimately involves making commitments.l2s By commitments, Finnis is
referring to definitive objectives that are participated in as basic aspects ofhuman good.r2a In
other words, one must see their life as one whole. not lavoring on moment over another, and

harmonizing one's commitments in order to "estabtish the proper perspective for choosing how to
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live one's present life."l25 The Orphan Drug Act satisfies the first principle because it has a
harmonious and coherent set ofpurposes all of which are focused on the basic aspects ofhuman
good.

b.

Second Principle

The second principle is to only prefer certain lbrms ofgood when it is rational to a
commitment.126 When determining

if

the prelerence is rational, one must base one's assessments

on "one's capacities, circumstances, and even one's taste."l27 Not having the capacity for a real

form ofgood is allowable and distinguishable from arbitrarily denying one of the seven goods as
forms of excellence.r28 However, the Orphan Drug Act falls short when judged under both the
second principle. When

it was first enacted, the act

seemed to align

with this, but

as

demonstrated in the seven basic goods analysis, has since then failed. The Orphan Drug Act,
through its effects, has arbitrarily denied some ofthe seven goods: tife, knowledge, and

sociability. The FDA has not taken any action, despite its knowledge olthe disparities in
treatment distribution, segregation ofpersons by the profit that can be achieved from their
respective diseases, and the resulting death and suffering from those whose diseases are not

lucrative. The excuse ofmoney is not a rational reason for this preference, because it was
previously shown that pharmaceutical companies do in fact have the capacity to research and
develop treatments for rare diseases, even when those therapeutic molecules diseases will result

in little profit. Thus, it can be deduced that the FDA and the pharmaceutical companies have
arbitrarily denied more than one ofthe seven basic goods. While the act itselfcannot control
these results, amendments to the act would, leading to the conclusion that the act, as is, is unjust.
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c.

Third Principle

The third principle is applying the same rule above to persons; that there should be no

arbitrary preference among persons.l2e In short, Finnis allows for a reasonable scope for selfpreference, but urges that one should still follow the "Golden Rule": do unto others what you

would have them do to you.130 The Orphan Drug Act also fails under the third principle in the
present day, but not in its enactment itself. In 1983, the Orphan Drug Act gave preference to
some persons over others, specifically preferring those afflicted by rare diseases and conditions.

However, this distinction was not arbitrary and instead was done in order to promote the goods
Finnis' theory encompasses. However, today it is apparent that the rare disease community has
been sliced in half arbitrarily. As discussed above, lucrative opportunities are not a rational
reason to deny some persons the rights that others are granted.

It

goes directly against the natural

rights all persons are entitled to and directly conflicts with the Golden Rule.

d.

Fourth and Fifih Principles

The fourth and fifth requirements are complementary to each other.rlr The fourth
requirement, detachment, is necessary "in order to be sufficiently open all the basic forms

of

good in all the changing circumstances of a lifetime, and in all one's relations, often
unforeseeable, with other persons, and in all one's opportunities ofeffecting their well-being."l32

For example, one should not consider one's life to be drained of meaning just because a project
or objective one took up failed.r33 On the other hand, the fifth requirement, commitment,
establishes a balance between complete and otter detachment, e.g., apathy and unreasonable
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failure, with fanaticism.l3a The result of this balance is that commitments must be made,
followed through, and not abandoned lightly.rs5 One should also seek to improve their
commitments by looking for new ways to carry them out.136 In regards to the Orphan Drug Act,
the

fou(h

and

fifth principles can be used as more ofa reflective standard to

have both followed through with their commitments and

see

ilthe legislators

if they have continually sought to

improve them. The answer is no to both issues. When the Orphan Drug Act was passed, the FDA
made a commitment to achieve the particular purpose of promoting the creation of therapeutic

molecules for rare diseases. However, it has since then abandoned the enfbrcement ofthe
purpose, even though the Orphan Drug Act is still good law. The abandonment is evident in the

clear failure ofthe law to have a given effect, leaving one to infer that the FDA has become
detached from the failure
amendments to

ofthe objective. The FDA

has also 1'ailed to improve the act through

fix these failures, in violation of the fifth principle Finnis describes. The Orphan

Drug Act, being govemed by the FDA. becomes the victim of the FDA's inaction, resulting in a
once ethical and well-intended law being apptied in such a way that now currently violates

natural law.

e.

Sixth Principle

The sixth requirement is recognizing the limited relevance ofconsequences in order to

bring good in the world through efficient actions that have a reasonable purpose.l3T Such actions
are

judged by their effectiveness, fitness for their purpose, utility. and consequences.rr8

Ultimately, the sixth requirement relies on being efficient in pursuing certain goals while
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avoiding harms that we regard as unacceptable.l3e This conduct has various applications in both
moral and legal thinking.rao When the House of Representatives passed the Orphan Drug Act, it
was drafted in consideration ofthe harms present in the pharmaceutical industry. The action

of

its enactment, in some sense, has certainly been effective in its benelits which is intertwined by
the

utility it brings: it helps an even larger population ofpeople in comparison to the number of

people that were helped prior to 1983. Thus, in one sense, the Orphan Drug Act is compliant

with the sixth principle. However, if its impact modem day is the standard, the emphasis remains
on the consequences

ofthe Orphan Drug Act that were discussed through the criticisms of the

act. These consequences are unacceptable, even with

utility considerations. Thus, the FDA's

conduct, or lack thereof, in fixing the defective Orphan Drug Act causes the act to become

immoral because it is ineffective in a large amount of the population encompassing those with
rare and nonlucrative conditions. Conversely, the positive elfects ofthe people who have could
therapeutic and curative treatments as a result ofthe Orphan Drug Act cannot be ignored and tips
the scales towards a moral conclusion. Therefore, the Orphan Drug Act when analyzed using the
standard set forth by Finnis' sixth requirement is objectively inconclusive, but subjectively could
become either moral or immoral depending on the value you place on the benefits versus the
consequences.

f.

Seventh Principle

The seventh requirement is to respect the seven basic lorms ofhuman good in every
action one takes.r4r Additionally, one should not willingly choose "any act which ofitselfdoes

nothing but damage or impede a realization or participation ofany one or more olthe basic
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forms ofhuman good."la2 This principle is parallel to the seven basic goods analysis previously
discussed. In sum, life, knowledge, and sociability are all satisfied in the action

olthe enactment

of the Orphan Drug Act and the Orphan Drug Act's text itself. However. the effects of the
Orphan Drug Act and the pharmaceutical companies' abuse of it impedes the participation in
more than one ofthe seven basic goods. Consequently, the law is moral, but its eff'ects are

immoral. Over time, these effects strip the morality of the law which is why the need for
amendments is undeniably crucial.

g.

Eighth Principle

The eighth requirement is merely a respect for the common good, that is to say, favoring
and fostering the common good in one's community.lll The Orphan Drug Act both promotes and

violates the common good, depending on how its framed. In one sense, the Orphan Drug Act
promotes the common good in the simple fact that more people are now being helped.
Conversely, when the entire population is considered, the Orphan Drug Act incentivizes
pharmaceutical companies to put their time into researching and developing treatments for a

small number ofpeople. The creation ofthese treatments is costly, and an argument could be
made that these costs could instead focus solely on common diseases. The core

ofthe argument

lies in utilitarian ideals, that if treatments and cures were even more available for larger
populations. the common good would be satisfied in that it benefits a majority ofthe population.
However, this is not how Finnis would frame the common good. The next section will discuss

this further, but Finnis'idea of the common good in the realm of natural law and rights is rooted
in justice and equality. Finnis defines equatity in a way that differs from utilitarianism: equality
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should be proportionate to create an equilibrium.lar Thus, since the Orphan Drug Act promotes
an equilibrium by addressing the problems

ofa population in need, the Orphan Drug Act

does, in

fact, contribute to the common good and promotes the natural rights all humans are entitled to.

h.

Ninth Principle

The final and ninth requirement is following one's conscience: "one should not do what
one judges or thinks or

'feels'-all-in-all should not be done."ll5 This principle is the principle

that is least applicable to the Orphan Drug Act since it is an intemal and subjective
determination. Thus, an objective analysis cannot be made as to how Orphan Drug Act strikes
the individual conscience. It is up to the reader to make their own determination, given the data,
whether the Orphan Drug Act and its effects "feel" right. My personal inclination is that the
Orphan Drug Act is theoretically moral, but changes to it would promote the seven basic goods
even more in order to

xI.

fully satisfy the ethical considerations Finnis proposes.

Three Elements of Justice
Lastly, Finnis discusses the three elements ofjustice as the final step in the algorithm

ol

determining the morality of an action, or in this case. a law. The first element is called "otherdirectedness," which relates to one's relations with others from an "'inter-subjective' or

interpersonal" standpoint.ra6 The second element ofjustice is the concept ofthe duty to provide
other persons what is due to them; their natural rights.llT The third element is proportional
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equality so that a balance is reached in society.la8 Since the first element is an interpersonal
element ofjustice, the following evaluation will focus on the lafter two elements.
Under Finnis' theory ofjustice, the justness ofthe law can be determined by inquiring as

to whether the law provides proper rights the targeted persons and whether the law promotes
proportional equality. As has often been the case through the entirety olthe paper, the law itself
is just, but its effects contradict that conclusion, as they are immoral, unethical, and defy the

purpose of the act. In the interest of non-repetition, the reasons for this conclusion will be briefly
addressed. The Orphan Drug Act provided rights of life to persons who did not have such

opportunities prior to its enactment. In fact, prior to 1983, the community ofthose alflicted by
rare diseases were frankly ignored, had no hope lor therapeutic or curative molecules, and were

simply damned to a life of suffering and inevitable death. Thus, the Orphan Drug Act is fair in
that it changed that clear disparity through distributive justice, giving the rare disease community
what was due to them in a way to promotes proportional equality. Conversely, the
pharmaceutical industry has displayed through their commercially valuable opportunity
preference in producing new therapies that this is violating the just intentions behind the Orphan

Drug Act. Pharmaceutical manufacturers are denying a population the rights due to them through
natural law and are segregating the rare disease community instead olseeing all members as
equal. The only solution to remedy this paradox is to redraft the law in such a way that limits the

ability of pharmaceutical companies to participate in these immoral practices so that morality in
all aspects can be restored.

XII.
ra8

Conclusion

Finnis, supra note 106, at 165.
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The Orphan Drug Act will continue to be abused by the pharmaceutical industry unless
is amended to restore

it

it to its original purpose. At its core. the policy considerations behind the

amendment should above all focus on faimess as defined by Finnis. The effects ofthe Orphan

Drug Act have allowed pharmaceutical companies to make "arbitrary" decisions as to whose
diseases are more important than others. Said

dilferently, they have decided whose lives are

more deserving of treatment than others. The use ofthe word "arbitrary" is used in the sense that

Finnis uses it, not in its literal definition. Finnis through his seven fundamental goods and three
elements ofjustice makes

it clear that lucrative opportunities, in this context, are not

a

rational

reason to choose certain lives over others. The Orphan Drug Act aimed to achieve true f'aimess

in the medical community: equal access to treatments, no matter the disease. Yel. as currently

written, the Orphan Drug Act inadvertently allows manufacturers to directly inhibit that access
through developing drugs for a narrow therapeutic set olfamilies and by charging absurdly high
prices for the therapies that do exist. What is most important is to raise awareness to elected

officials and the medical community at large tbr the rare disease community.

r,r,ho are

still in the

same place as they were before the Orphan Drug Act was even passed. Fair access and treatment
are the major policies behind the Orphan Drug Act and in order for those purposes to be properly

canied out, the Orphan Drug Act should change their incentives in order to promote equal access
to therapeutic molecules that can provide a better quality of tife to those who never had
treatment, to begin with. Unless this critical assessment and change is made. millions

of

members of the rare disease community will be damned to a limited lit'e of sufflering, with no
hope for a better tomorrow.
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